Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult

Neuroscience

Volumn 147, Issue 3, 2007, Pages 592-598

  Behrouz, B ^a   Drolet, R E ^a   Sayed, Z A ^a   Lookingland, K J ^a,b   Goudreau, J L ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

hypothalamus; MPTP; neurodegeneration; rotenone; susceptibility; tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; MITOCHONDRIAL COMPLEX I; OXIDOREDUCTASE; ROTENONE; TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN REGION; DOPAMINERGIC NERVE CELL; MOUSE; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TUBEROHYPOPHYSEAL TRACT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; ARCUATE NUCLEUS; BRAIN CHEMISTRY; BRAIN STEM; CELL COUNT; CELLS, CULTURED; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX I; MALE; MICE; MPTP POISONING; NEURONS; NEUROTOXINS; ROTENONE; TYROSINE 3-MONOOXYGENASE;

EID: 34250868881     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.05.007     Document Type: Article

References (44)

1. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
2. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
3. Braak H., and Braak E. Pathoanatomy of Parkinson's disease. J Neurol 247 Suppl 2 (2000) II3-II10
4. Bywood P.T., and Johnson S.M. Mitochondrial complex inhibitors preferentially damage substantia nigra dopamine neurons in rat brain slices. Exp Neurol 179 (2003) 47-59
5. Chan P., DeLanney L.E., Irwin I., Langston J.W., and Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 57 (1991) 348-351
6. Cosi C., and Marien M. Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann N Y Acad Sci 890 (1999) 227-239
7. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
8. Drolet R.E., Behrouz B., Lookingland K.J., and Goudreau J.L. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25 (2004) 761-769
9. Fearnley JM, Lees AJ Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5):2283-2301.
10. Franklin K.B.J., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic Press, San Diego
11. German D.C., Manaye K., Smith W.K., Woodward D.J., and Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 26 (1989) 507-514
12. German D.C., Manaye K.F., Sonsalla P.K., and Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 648 (1992) 42-62
13. Greene J.G., Dingledine R., and Greenamyre J.T. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis 18 (2005) 19-31
14. Gundersen H.J., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147 Pt 3 (1987) 229-263
15. Hirsch E.C. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?. Ann Neurol 32 Suppl (1992) S88-S93
16. Hirsch E.C., Faucheux B., Damier P., Mouatt-Prigent A., and Agid Y. Neuronal vulnerability in Parkinson's disease. J Neural Transm Suppl 50 (1997) 79-88
17. Hung H.C., Tao P.L., and Lee E.H. 1-Methyl-4-phenyl-pyridinium (MPP+) uptake does not explain the differential toxicity of MPP+ in the nigrostriatal and mesolimbic dopaminergic pathways. Neurosci Lett 196 (1995) 93-96
18. Langston J.W., and Forno L.S. The hypothalamus in Parkinson disease. Ann Neurol 3 (1978) 129-133
19. Lau Y.S., Trobough K.L., Crampton J.M., and Wilson J.A. Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen Pharmacol 21 (1990) 181-187
20. Le W., Conneely O.M., Zou L., He Y., Saucedo-Cardenas O., Jankovic J., Mosier D.R., and Appel S.H. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol 159 (1999) 451-458
21. Lindley S.E., Gunnet J.W., Lookingland K.J., and Moore K.E. 3,4-Dihydroxyphenylacetic acid concentrations in the intermediate lobe and neural lobe of the posterior pituitary gland as an index of tuberohypophysial dopaminergic neuronal activity. Brain Res 506 (1990) 133-138
22. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., Brecha N., and Edwards R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70 (1992) 539-551
23. Lookingland K.J., and Moore K.E. Functional neuroanatomy of hypothalamic dopaminergic neuroendocrine systems. In: Dunnett S.B., et al. (Ed). Handbook of chemical neuroanatomy Vol. 21 (2005), Elsevier, Amsterdam 433-521
24. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275 (2000) 38581-38588
25. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
26. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
27. Melamed E., Rosenthal J., Globus M., Cohen O., Frucht Y., and Uzzan A. Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice. Eur J Pharmacol 114 (1985) 97-100
28. Mogi M., Harada M., Kojima K., Kiuchi K., and Nagatsu T. Effects of systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mice on tyrosine hydroxylase, L-3,4-dihydroxyphenylalanine decarboxylase, dopamine beta-hydroxylase, and monoamine oxidase activities in the striatum and hypothalamus. J Neurochem 50 (1988) 1053-1056
29. Palkovits M. Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res 59 (1973) 449-450
30. Petroske E., Meredith G.E., Callen S., Totterdell S., and Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106 (2001) 589-601
31. Reinhard Jr. J.F., Diliberto Jr. E.J., Viveros O.H., and Daniels A.J. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci U S A 84 (1987) 8160-8164
32. Saporito M.S., Thomas B.A., and Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 75 (2000) 1200-1208
33. Schmitz C. Towards more readily comprehensible procedures in disector stereology. J Neurocytol 26 (1997) 707-710
34. Schmitz C., and Hof P.R. Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J Chem Neuroanat 20 (2000) 93-114
35. Schmitz C., and Hof P.R. Design-based stereology in neuroscience. Neuroscience 130 (2005) 813-831
36. Smeyne M., and Smeyne R.J. Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease. Brain Res Brain Res Protoc 9 (2002) 105-111
37. Sundstrom E., Fredriksson A., and Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res 528 (1990) 181-188
38. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405 (1987) 26-38
39. Takamidoh H., Naoi M., and Nagatsu T. Inhibition of type A monoamine oxidase by 1-methyl-4-phenylpyridine. Neurosci Lett 73 (1987) 293-297
40. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100 (2003) 5473-5478
41. Uhl G.R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43 (1998) 555-560
42. West M.J., Slomianka L., and Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231 (1991) 482-497
43. Willis G.L., and Donnan G.A. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 402 (1987) 269-274
44. Zang L.Y., and Misra H.P. Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Biol Chem 268 (1993) 16504-16512